Nebivolol improves diastolic dysfunction and myocardial remodeling through reductions in oxidative stress in the transgenic (mRen2) rat

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 302, Issue 11, 2012, Pages

  Ma, Lixin ^a,b   Gul, Rukhsana ^a,b   Habibi, Javad ^a,b   Yang, Ming ^a,b   Pulakat, Lakshmi ^a,b   Whalev Connell, Adam ^a,b   Ferrario, Carlos M ^c   Sowers, James R ^a,b  

^a University of Missouri   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Diastolic relaxation time; Insulin resistance; Magnetic resonance imaging

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; HEME OXYGENASE; NEBIVOLOL; NITRIC OXIDE; PEROXYNITRITE; PLACEBO; PROTEIN KINASE B; PROTEIN P47; RAC1 PROTEIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FIBROSING ALVEOLITIS; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; INSULIN RESISTANCE; MALE; NONHUMAN; OSMOTIC MINIPUMP; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; RELAXATION TIME; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; ANIMALS; BENZOPYRANS; DIASTOLE; DISEASE MODELS, ANIMAL; ETHANOLAMINES; FIBROSIS; HYPERTROPHY, LEFT VENTRICULAR; MALE; MYOCARDIUM; NADPH OXIDASE; NITRIC OXIDE; OXIDATIVE STRESS; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, SPRAGUE-DAWLEY; RATS, TRANSGENIC; RENIN; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84861762743     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.01126.2011     Document Type: Article

References (56)

1. Amundsen BH, Ericsson M, Seland JG, Pavlin T, Ellingsen ø, Brek-ken C. A comparison of retrospectively self-gated magnetic resonance imaging and high-frequency echocardiography for characterization of left ventricular function in mice. Lab Anim 45: 31-37, 2011.
2. Beauloye C, Bertrand L, Horman S, Hue L. AMPK activation, a preventive therapeutic target in the transition from cardiac injury to heart failure. Cardiovasc Res 90: 224-233, 2011.
3. Berk BC, Fujiwara K, Lehoux S. ECM remodeling in hypertensive heart disease. J Clin Invest 117: 568-575, 2007.
4. de Oliveira UO, Belló-Kein A, de Oliveira AR, Kuchaski LC, Machado UF, Irigoyen MC, Schaan BD. Insulin alone or with captopril: effects on signaling pathways (AKT and AMPK) and oxidative balance after ischemia-reperfusion in isolated hearts. Fundam Clin Pharmacol; doi:10.1111/j.1472-8206.2011.00995.x.
5. Ding B, Gibbs PE, Brookes PS, Maines MD. The coordinated increased expression of biliverdin reductase and heme oxygenase-2 promotes cardiomyocyte survival: a reductase-based peptide counters ββ-adrenergic receptor ligand-mediated cardiac dysfunction. FASEB J 25: 301-313, 2011.
6. Dixon LJ, Morgan DR, Hughes SM, McGrath LT, Elsherbeeny NA, Plumb RD, Devine A, Leahey W, Johnston GD, McVeigh GE. Functional consequences of endothelial nitric oxide synthase uncoupling in congestive cardiac failure. Circulation 107: 1725-1728. 2003.
7. Durante W, Kroll MH, Christodoulides N, Peyton KJ, Schafer AI. Nitric oxide induces heme oxygenase-1 gene expression and carbon monoxide production in vascular smooth muscle cells. Circ Res 80: 557-564, 1997.
8. Fang Y, Nicol L, Harouki N, Monteil C, Wecker D, Debunne M, Bauer F, Lallemand F, Richard V, Thuillez C, Mulder P. Improvement of left ventricular diastolic function induced by β3-blockade: a comparison between nebivolol and metoprolol. J Mol Cell Cardiol 51: 168-176, 2011.
9. Farhangkhoee H, Khan ZA, Mukherjee S, Cukiernik M, Barbin YP, Karmazyn M, Chakrabarti S. Heme oxygenase in diabetes-induced oxidative stress in the heart. J Mol Cell Cardiol 35: 1439-1448, 2003.
10. Ghio S, Magrini G, Serio A, Klersy C, Fucili A, Ronaszeki A, Karpati P, Mordenti G, Capriati A, Poole-Wilson PA, Tavazzi L. Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. Eur Heart J 27: 562-568, 2006.
11. Ginion A, Auquier J, Benton CR, Mouton C, Vanoverschelde JL, Hue L, Horman S, Beauloye C, Bertrand L. Inhibition of the mTOR/p70S6K pathway is not involved in the insulin-sensitizing effect of AMPK on cardiac glucose uptake. Am J Physiol Heart Circ Physiol 301: H469-H477, 2011.
12. Gundewar S, Calvert JW, Jha S, Toedt-Pingel I, Ji SY, Nunez D, Ramachandran A, Anaya-Cisneros M, Tian R, Lefer DJ. Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure. Circ Res 104: 403-411, 2009.
13. Gupta S, Wright HM. Nebivolol: a highly selective ββ1-adrenergic receptor blocker that causes vasodilation by increasing nitric oxide. Cardiovasc Ther 26: 189-202, 2008.
14. Habibi J, DeMarco VG, Ma L, Pulakat L, Rainey WE, Whaley-Connell A, Sowers JR. Mineralocorticoid receptor blockade improves diastolic function independent of blood pressure reduction in transgenic model of RAAS overexpression. Am J Physiol Heart Circ Physiol 300: H1484-H1491, 2011.
15. Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest 100: 2153-2157, 1997.
16. Hwang YP, Kim HG, Hien TT, Jeong MH, Jeong TC, Jeong HG. Puerarin activates endothelial nitric oxide synthase through estrogen receptor-dependent PI3-kinase and calcium-dependent AMP-activated protein kinase. Toxicol Appl Pharmmacol 257: 48-58, 2011.
17. Ibrahimzel SH, Miller AB, White RD. The relationship between aortic stiffness and E/A filling ratio and myocardial strain in the context of left ventricular diastolic dysfunction in heart failure with normal ejection fraction: insights from magnetic resonance imaging. Magn Reson Imaging 29: 1222-1234, 2011.
18. Kahn BB, Alquier T, Carling D, Hardie DG. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 1: 15-25, 2005.
19. Kane GC, Karon BL, Mahoney DW, Redfield MM, Roger VL, Burnett JC Jr, Jacobsen SJ, Rodeheffer RJ. Progression of left ventricular diastolic dysfunction and risk of heart failure. JAMA 306: 856-63, 2011.
20. Kanski J, Behring A, Pelling J, Schoneich C. Proteomic identification of 3-nitrotyrosine-containing rat cardiac proteins: effects of biological aging. Am J Physiol Heart Circ Physiol 288: H371-H381, 2005.
21. Kitzman DW, Little WC, Brubaker PH, Anderson RT, Hundley WG, Stewart KP, Marburger CT, Brosnihan B, Morgan TM, Wesley DJ. Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA 288: 2144-2150, 2002.
22. Li JM, Gall NP, Grieve DJ, Chen M, Shah AM. Activation of NADPH oxidase during progression of cardiac hypertrophy to failure. Hypertension 40: 477-484. 2002.
23. Lira VA, Soltow QA, Long JHD, Betters JL, Sellman JE, Criswell DS. Nitric oxide increases GLUT4 expression and regulates AMPK signaling in skeletal muscle. Am J Physiol Endocrinol Metab 293: E1062-E1068, 2007.
24. Long YC, Cheng Z, Copps KD, White MF. Insulin receptor substrates Irs1 and Irs2 coordinate skeletal muscle growth and metabolism via the Akt and AMPK pathways. Mol Cell Biol 31: 430-441, 2011.
25. Manrique C, Lastra G, Habibi J, Pulakat L, Schneider R, Durante W, Tilmon R, Rehmer J, Hayden MR, Ferrario CM, Whaley-Connell A, Sowers JR. Nebivolol improves insulin sensitivity in the TGR(Ren2)27 rat. Metabolism 60: 1757-1766, 2011.
26. Marazzi G, Volterrani M, Caminiti G, Iaia L, Massaro R, Vitale C, Sposato B, Mercuro G, Rosano G. Comparative long term effects of nebivolol and carvedilol in hypertensive heart failure patients. J Card Fail 17: 703-709, 2011.
27. Martos R, Baugh J, Ledwidge M, O'Loughlin C, Conlon C, Patle A, Donnelly SC, McDonald K. Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation 115: 888-895, 2007.
28. Munzel T, Daiber A, Ullrich V, Mulsch A. Vascular consequences of endothelial nitric oxide synthase uncoupling for the activity and expression of the soluble guanylyl cyclase and the cGMP-dependent protein kinase. Arterioscler Thromb Vasc Biol 25: 1551-1557, 2005.
29. Nagata D, Takeda R, Sata M, Satonaka H, Suzuki E, Nagano T, Hirata Y. AMP-activated protein kinase inhibits angiotensin II-stimulated vascular smooth muscle cell proliferation. Circulation 110: 444-451, 2004.
30. Nakao K, Minobe W, Roden R, Bristow MR, Leinwand LA. Myosin heavy chain gene expression in human heart failure. J Clin Invest 100: 2362-2370. 1997.
31. Nodari S, Metra M, Dei CL. Beta-blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long-term effects of atenolol vs nebivolol. Eur J Heart Fail 5: 621-627, 2003.
32. Oelze M, Daiber A, Brandes RP, Hortmann M, Wenzel P, Hink U, Schulz E, Mollnau H, von Sandersleben A, Kleschyov AL, Mülsch A, Li H, Förstermann U, Müünzel T. Nebivolol inhibits superoxide formation by NADPH oxidase and endothelial dysfunction in angiotensin II-treated rats. Hypertension 48: 677-684, 2006.
33. Ramamurthy S, Ronnett GV. Developing a head for energy sensing: AMP-activated protein kinase as a multifunctional metabolic sensor in the brain. J Physiol 574: 85-93, 2006.
34. Redfield MM. Understanding diastolic heart failure. N Engl J Med 350: 1930-1931, 2004.
35. Sawyer DB, Siwik DA, Xiao L, Pimentel DR, Singh K, Colucci WS. Role of oxidative stress in myocardial hypertrophy and failure. J Mol Cell Cardiol 34: 379-388, 2002.
36. Schopfer FJ, Baker PRS, Freeman BA. NO-dependent protein nitration: a cell signaling event or an oxidative inflammatory response? Trends Biochem Sci 28: 646-654, 2003.
37. Sciarretta S, Paneni F, Palano F, Chin D, Tocci G, Rubattu S, Volpe M. Role of the renin-angiotensin-aldosterone system and inflammatory processes in the development and progression of diastolic dysfunction. Clnn Sci (Lond) 116: 467-477, 2009.
38. Shahbaz AU, Sun Y, Bhattacharya SK, Ahokas RA, Gerling IC, McGee JE, Weber KT. Fibrosis in hypertensive heart disease: molecular pathways and cardioprotective strategies. J Hypertens 28, Suppl 1: S25-S32, 2010.
39. Solak Y, Atalay H. Nebivolol in the treatment of metabolic syndrome: making the fat more brownish. Med Hypotheses 74: 614-615, 2010.
40. Sorescu D, Griendling KK. Reactive oxygen species, mitochondria, and NAD(P)H oxidases in the development and progression of heart failure. Congest Heart Fail 8: 132-140, 2002.
41. Sorrentino SA, Doerries C, Manes C, Speer T, Dessy C, Lobysheva I, Mohmand W, Akbar R, Bahhnann F, Besler C, Schaefer A, Hilfiker-Kleiner D, Lüscher TF, Balligand JL, Drexler H, Landmesser U. Nebivolol exerts beneficial effects on endothelial function, early endothelial progenitor cells, myocardial neovascularization, and left ventricular dysfunction early after myocardial infarction beyond conventional β1-blockade. J Am Coll Cardiol 57: 601-611, 2011.
42. Stuckey DJ, Carr CA, Tyler DJ, Clarke K. Cine-MRI versus two-dimensional echocardiography to measure in vivo left ventricular function in rat heart. NMR Biomed 21: 765-772, 2008.
43. Sun Y, Ramires FJA, Zhou G, Ganjam VK, Weber KT. Fibrous tissue and angiotensin II. J Mol Cell Cardiol 29: 2001-2012, 1997.
44. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev 79: 215-262, 1999.
45. Takimoto E, Kass DA. Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension 49: 241-248, 2007.
46. Tian R, Musi N, D'Agostino J, Hirshman MF, Goodyear LJ. Increased adenosine monophosphate-activated protein kinase activity in rat hearts with pressure-overload hypertrophy. Circulation 104: 1664-1669, 2001.
47. Turdi S, Fan X, Li J, Zhao J, Huff AF, Du M, Ren J. AMP-activated protein kinase deficiency exacerbates aging-induced myocardial contractile dysfunction. Aging Cell 9: 592-606. 2010.
48. Tsika RW, Ma L, Kehat I, Schramm C, Simmer G, Morgan B, Fine DM, Hanft LM, McDonald K., Molkentin JD, Krenz M, Yang S, Ji J. TEAD-1 overexpression in the mouse heart promotes an age-dependent heart dysfunction. J Biol Chemm 285: 13721-35, 2010.
49. van Veldhuisen DJ, Cohen-Solal A, Böhm M, Anker SD, Babalis D, Roughton M, Coats AJ, Poole-Wilson PA, Flather MD; SENIORS Investigators. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardlol 53: 2150-2158, 2009.
50. Whaley-Connell A, Govindarajan G, Habibi J, Hayden MR, Cooper SA, Wei Y, Ma L, Qazi M, Karuparthi PR, Stump C, Ferrario C, Sowers JR. Angiotensin-II mediated oxidative stress promotes myocardial tissue remodeling in the transgenic TG (mRen2) 27 Ren2 rat. Am J Physiol Endocrinol Metab 293: E355-E363, 2007.
51. Whaley-Connell A, Habibi J, Johnson M, Tilmon R, Rehmer N, Rehmer J, Wiedmeyer C, Ferrario CM, Sowers JR. Nebivolol reduces proteinuria and renal NADPH oxidase-generated reactive oxygen species in the transgenic Ren2 rat. Am J Nephrol 30: 354-360, 2009.
52. Xu S, Ying J, Jiang B, Guo W, Adachi T, Sharov V, Lazar H, Menzoian J, Knyushko TV, Bigelow D, Schoneich C, Cohen RA. Detection of sequence-specific tyrosine nitration of manganese SOD and SERCA in cardiovascular disease and aging. Am J Physiol Heart Circ Physiol 290: H2220-H2227, 2006.
53. Yu CM, Lin H, Yang H, Kong SL, Zhang Q, Lee SW. Progression of systolic abnormalities in patients with isolated diastolic heart failure and diastolic dysfunction. Circulation 105: 1195-1201, 2002.
54. Zhang H, Morgan B, Potter BJ, Ma L, Dellsperger KC, Ungvari Z, Zhang C. Resveratrol improves left ventricular diastolic relaxation in type 2 diabetes by inhibiting oxidative/nitrative stress: in vivo demonstration with magnetic resonance imaging. Am J Physiol Heart Circ Physiol 299: H985-H994, 2010.
55. Zhou X, Ma L, Habibi J, Whaley-Connel AT, Hayden MR, Tilmon RD, Brown AN, DeMarco VG, Sowers JR. Nebivolol improves diastolic dysfunction and myocardial tissue remodeling through reductions in oxidative stress in the Zucker obese rat. Hypertension 55: 880-888, 2010.
56. Zobel C, Zavidou-Saroti P, Bolck B, Brixius K, Reuter H, Frank K, Diedrichs H, Müller-Ehmsen J, Bloch W, Schwinger RH. Altered tension cost in (TG(mREN-2)27) rats overexpressing the mouse renin gene. Eur J Appl Physiol 99: 121-132, 2007.